Low-density lipoprotein apheresis using the liposorber system: Features of the system and clinical benefits

Therapeutic Apheresis

Volumn 2, Issue 1, 1998, Pages 25-30

  Yamamoto, T ^a   Yamashita, T ^a  

^a KANEKA CORPORATION   (Japan)

Author keywords

Arteriosclerosis obliterans; Dextran sulfate; Familial hypercholesterolemia; Focal glomerular sclerosis; Liposorber system; Low density lipoprotein apheresis

Indexed keywords

ANTILIPEMIC AGENT; BRADYKININ; CELLULOSE; DEXTRAN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SORBENT;

ATHEROSCLEROTIC PLAQUE; BRACHIAL ARTERY; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIET THERAPY; ENDOTHELIUM CELL; EXTRACORPOREAL CIRCULATION; FAMILIAL HYPERCHOLESTEROLEMIA; GLOMERULOSCLEROSIS; HEMADSORPTION; HUMAN; HYPOTENSION; NAUSEA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; VERTIGO; VOMITING;

EID: 0031807324     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1998.tb00069.x     Document Type: Review

References (42)

1. ® LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. Curr Ther Res 1994;8:879-904.
2. Tani N. Development of selective low-density lipoprotein (LDL) apheresis system: Immobilized polyanion as LDL-specific adsorption for LDL apheresis system. Artif Organs 1996;8:922-9.
3. Koizumi J, Koizumi I, Uno Y, Inazu A, Kajinami K, Haraki T, Yagi K, Kamon N, Miyamoto S, Takegoshi T, Mabuchi H, Takeda R, Tani N, Takada S. Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 1993;100:65-74.
4. Gordon BR, Kelsey SF, Biheimer DW, Brown DC, Dau PC, Gotto AM Jr, Illingworth DR, Jones PH, Leitman SF, Prihoda JS, Stein EA, Stern TN, Zavoral JH, Zwiener RJ, for the Liposorber Study Group. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1992;70:1010-6.
5. Kojima S, Harada-Shiba M, Toyota Y, Kimura G, Tsushima M, Kuramochi M, Sakata T, Uchida K, Yamamoto A, Omae T. Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992;15:185-90.
6. Yamamoto A, Kojima S, Shiba-Harada M, Kawaguchi A, Hatanaka K. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. Artif Organs 1992;16:177-81.
7. Knisel W, Di Nicuolo A, Pfohl M, Muller H, Risler T, Eggstein M, Seifried E. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. J Intern Med 1993;234:479-87.
8. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A, Goto Y, for the LARS investigators. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: A multicenter study. Atherosclerosis 1992;95: 1-13.
9. Nishimura S, Yamaguchi H, L-CAPS group investigators. Regression of coronary atherosclerosis by intensive lipid-lowering therapy with combined LDL-apheresis and drugs in familial hypercholesterolemia: Japan LDL-Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Circulation 1994;90(Suppl. 1):1-510.
10. Kitabatake A, Sato H, Hori M, Kamada T, Kubori S, Hoki N, Minamino T, Yamada M, Kato T, for the Osaka LDL-Apheresis Multicenter Trial Group. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein apheresis: 1 year follow-up study. Clin Ther 1994;16:416-28.
11. Kroon AA, Aengevaeren WRM, van der Werf T, Uijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFH. LDL-apheresis atherosclerosis regression study (LAARS): Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
12. Aengevaeren WRM, Kroon AA, Stalenhoef AFH, Uijen GJH, van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease: The LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996;28:1696-704.
13. Kroon AA, van Asten WNJC, Stalenhoef AFH. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-54.
14. Koga N. The retardation of progression, stabilization and regression of coronary and carotid atherosclerosis by LDL-apheresis in patients with familial hypercholesterolemia. Ther Apheres 1997;6:260-70.
15. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial hypercholesterolaemia regression study: A randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
16. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
17. Koga N, Iwata Y. Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia. Atherosclerosis 1991;90:9-21.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
19. Mabuchi H. LDL-apheresis and gene therapy. J Jpn Atheroscler Soc (abstract: Japanese) 1997;24:648.
20. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-9.
21. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
22. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91:29-37.
23. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341:1496-500.
24. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89: 2519-24.
25. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
26. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme a reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
27. Igarashi K, Horimoto M, Takenaka T, Inoue H, Miyata S. Acute cholesterol lowering therapy with LDL-apheresis improves endothelial function of the coronary microcirculation in patients with hypercholesterolemia. Circulation 1995;92(Suppl. I):I-452.
28. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
29. Leitinger N, Pirich C, Blazek I, Endler G, Sinzinger H. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis 1996;126:305-12.
30. Napoli C, Ambrosio G, Scarpato N, Corso G, Palumbo G, D'Armiento FP, Mancini FP, Malorni A, Formisano S, Ruocco Antonio, Cali Antonio, Chiariello M. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 1997;5:585-95.
31. Inoue I, Kikuchi C, Takahashi K, Katayama S. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment. Diabetes Care 1996;19:1103-7.
32. Uno H, Ueki Y, Murashima J, Miyake S, Tominaga Y, Eguchi K, Yano K. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerotic obliterance. Atherosclerosis 1995;116: 93-102.
33. Sinzinger H, Pirich C, Bednar J, O'Grady J. Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis. Thromb Res 1996;82: 291-301.
34. Rubba P, Iannuzzi A, Postiglione A, Scarpato N, Montefusco S, Gnasso A, Nappi G, Cortese C, Mancini M. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990;81:610-6.
35. Naganuma S, Agishi T, Ota K. Low density lipoprotein apheresis in atherosclerosis disease with hyperlipidemia. Ther Plasmapheresis 1993;12:439-41.
36. Naganuma S, Agishi T, Ota K. Hemorheological effects of low density lipoprotein apheresis on atherosclerosis disease with hyperlipidemia. Ther Plasmapheresis 1993;12:443-5.
37. Koenig W, Ditschuneit H.H.M., Hehr R, Willi Grunewald R, Ernst E, Hombach V. Blood rheology after LDL apheresis using dextran sulfate cellulose adsorption-A case report. Angiology 1992;43:606-9.
38. Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 1994;9:257-64.
39. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulfate, and ACE inhibitors. Lancet 1992;340:908-9.
40. Kroon AA, Mol MJTM, Stalenhoef AFH. ACE inhibitors and LDL-apheresis with dextran sulfate adsorption. Lancet 1992;340:1476.
41. Keller C, Grutzmacher P, Bahr F, Schwarzbeck A, Kroon AA, Kiral A. LDL-apheresis with dextran sulfate and anaphylactoid reactions to ACE inhibitors. Lancet 1993;341:60-1.
42. Kojima S, Harada-Shiba M, Nomura S, Kimura G, Tsushima M, Kuramochi M, Yamamoto A, Omae T. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. ASAIO Trans 1991;37:644-8.